Member Info for HereforHemo

I would think the last thing on Vlads mind when running a clinical trial would be the AGM.

However, with patient one now passing the three month stage since their treatment Vlad would have received a report from the hospital on both primary (safety) and secondary (efficacy) objectives. Patient two will, all being well, reach the first 28 day milestone next week.

So, regardless of any RNS if Vlad looks happy and relaxed tomorrow then it's safe to say he's probably got something pretty special lined up in the not too distant future.

It's a very strong hold and accumulate for Mr.

Micky you are correct in that patients one and two may relapse, or a VC or pharmaceutical giant may not put in a suitable offer for a percentage of CAR-T, or indeed the company.

But equally patients one and two may respond exceptionally well to treatment and Hemogenyx may indeed receive very valuable offers from either a JV or a pharmaceutical company or both.

That’s why the SP is languishing where it is but if things move to a more promising outlook then it won’t stay anywhere near this level for much longer.

I’d say the reward very much outweighs the risk at this moment in time.

Patient two 28 day safety results out in the next two weeks and the very important patient one three month results for both safety and efficacy.

If they are as good as I expect then we should see a nice bounce in the SP as well as increasing interest from the major pharmaceutical companies.

I would have thought the best thing to do on a Hemogenyx bulletin board was to discuss progress with people invested in Hemogenyx.

If you’re not invested then as far as I am concerned you don’t exist and anything posted is totally irrelevant.

Why people feel the need to respond is beyond me.

I am in dialogue with quite a few of these individuals and yes, some would rather wait for a major pharmaceutical company to invest. But bearing in mind they'll probably invest off the back of HG-CT-1 being proven to be the best in class treatment for r/r AML and it being suitable for treating children, adolescents and adults, they are likely to have to buy in between £10-15 a share. Each to their own.

What people should be focusing on is the scientific progress.

*both patient one and two experienced no adverse effects from treatment which is unique when treating r/r AML.

*patient one is fast approaching their 3 month hospital report on both primary and secondary objectives where efficacy is reported as well as safety.

*patient two is also approaching their 28 day initial safety report.

*upon patient two's report patient three will be recruited and treated, all of which is fully funded.

Once patient three has been treated, and patient two has passed the initial safety guidelines Hemogenyx will quite possibly be in a position where only three of the next fifteen patients chosen need to do well in order to pass the Phase 1 trial and progress to Phase 2.

And if patient one's report shows CMR on efficacy then there is no doubt in my mind the next funding will come from a major, and well before patient four being treated.

We could well be a week away from the most transformational news in Hemogenyx’s history and that would lead to a massive rerate of the SP, even bigger than a major buying into the project.

A really exciting news rich period ahead. Time for calm minds and a cool head. IMO.

One thing that went unnoticed from today’s announcement was that by Hemogenyx expanding the trial into pediatrics they will also be treating a subset of ALL, which is prevalent in children. It’s worth noting that this market, as far as I can ascertain, is 50% larger than the AML market which if proven successful will undoubtedly add tens of not hundreds of millions of dollars to the value of the product.

https://www.lse.co.uk/rns/HEMO/strategic-investment-from-prevail-partners-llc-re84v9fv90tzezc.html

It's important to note that following the pediatric submission to the FDA that will include the current data, it's perfectly plausible that they amend the current schedule with a fast track for HG-CT-1 and allow Hemogenyx to treat patients concurrently.

I'm like a lot of posters on here, my expectation is for a major to step in after patient 3/4. I don't see any other reason for Vlad to have the discussions he's currently having if they were going to wait.

Solow if Hemogenyx had any concerns regarding funding they certainly wouldn't be looking to expand the trial into pediatrics.

My take is yes they'll probably need to raise another $500k through a non discounted offer and throw some warrants at them but that'll be enough to treat the initial four patients.

Then they can treat patients every two weeks, children, adolescents and adults. For sure I think Penn will become involved and all this will mean additional expense. But if won't be Hemogenyx funding it! At this stage, maybe two months or so away, Vlad will accept one of the many offers from a major.

All if course in my opinion.

#savinglives #billionsandyears

One thing I know for sure, Vlad said they would not progress with treating children with HG-CT-1 until the hospital were 100% sure it was safe.

They are now progressing pediatrics. This is a MAJOR endorsement of the product candidate both in its effectiveness and value.

Micky the FDA mandate that the first 4 patients are a month apart then we can treat them every two weeks.

My view is that we're due the hospital report on both the primary and secondary trial objectives for patient one, that will cover both safety and efficacy.

Subject to health I'd think patient two should be very close to receiving HG-CT-1 now.

It would seem Hemogenyx have received multiple offers of finance and a decision is required within the next 10 or so trading days.

Financial reports are also due next week which should also include a CDX and CBR status update.

Obviously we're all speculating at the moment but if I'm right we're in an extremely news rich period at the moment. All of it should be positive which in turn should lead to a substantial rerate of the SP so I still remain calm, confident and patient.

Hulver your view is wrong. Hemogenyx will be filing on time. 100% guaranteed.

With regards to pediatrics it's quite a simple answer, once the therapy is proven safe in adults the pediatric trial will commence.

Micky I'd agree with JHFH in that I think finance will be agreed by next month and it'll secure Hemogenyx’s future for at least a year and quite possibly for ever, as after four patients have been treated (3 more months) if results continue to be promising I expect a major to step in and take HG-CT-1 forward through the trial. If they do Hemogenyx will be fully funded for all their R&D and you'll have your exit price.

That's far too complicated for me.

I just ask myself, would Vlad be presenting on the safety and efficacy for patient one to one of the biggest pharmas in the world next week if the results weren't positive?

Patient One alive and well after 9 weeks with no adverse affects after treatment, so both safety and efficacy looking promising.

News coming on:

*Patient two injection.

*Patient One hospital report on secondary objectives.

*Non dilutive funding.

Looking forward to a strong week.

All in my opinion.

Let's be honest, the last placement was an absolute disgrace. In fact virtually without exception all their previous raises have been appalling, for one reason or another. Shareholders have suffered greatly and although people say Vlad doesn't care, I'm sure Vlad and his wife going from a multi million dollar holding and majority ownership to a few hundred thousand and less than 5% of the company must have stung, so I don't think it's cynical I just think it's financial incompetence.

But we are where we are and things have now changed. Rather than raising as an R&D company they are now a clinical company and although only one patient they have tangible data that will demonstrate not only the safety but efficacy as well. Basically they can demonstrate the product candidate works, which is huge when discussing finance options.

Vlad has talked for many years about candidates and or the company being worth billions. The imminent hospital results, patient two being treated and a finance agreement being agreed means Hemogenyx are at the most critical juncture in their history. And it's all going to happen in weeks not months imo.

I remain calm, confident and very hopeful.

Happy Easter to all.

Although the biopharmaceutical market seems a little subdued at the moment it's worth remembering that potential suiters for Hemogenyx or Hemogenyx product candidates such as HG-CT-1 are not exactly struggling. For example Gilead have $10 billion cash on hand, J&J have a massive $23.5 billion cash in hand and my personal pick for Hemogenyx is Bristol Myers who not only have $10 billion cash on hand, and an extensive CAR-T portfolio but are known to be on the acquisition trail. They also happen to be based in New York.

It may well be a premature discussion but as an investor that's where I see it going and when it does it'll be in the hundreds of millions, just for one product.

KP done

What we do know is the results published from the hospital next week will be the first visibility we get of the secondary objectives of the trial.

Key secondary objectives include assessing the therapy's impact on the following clinical outcomes:

· Efficacy of HG-CT-1 based on AML-specific response criteria

· Overall survival (OS) rates among participating subjects

· Progression-free survival (PFS) in evaluable subjects

· Duration of response (DoR) in those who achieve clinical responses.

These objectives are pivotal for assessing the overall clinical impact of HG-CT-1 on patients with R/R AML, a population with few remaining therapeutic options.

To date we know patient one experienced no adverse reaction to the treatment so safety looks good.

We also know people suffering from AML literally have weeks to live and to complement the statement that initial efficacy showed promise, next Tuesday marks EIGHT WEEKS into treatment.

Pointless attacking negative posts in my opinion. Just be patient and let the science deliver. Finance into Hemogenyx will follow which in turn will lead to value returning for holders.